AB Science SA

1,8000

21-января-25 10:29:52

15 мин. задержка

Акции

-0,0280

-1,53%

Сегодняшний диапазон

1,8000 - 1,8180

ISIN

FR0010557264

Источник

Cboe

AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND

02 сен 2021 10:59:01 Источник Nasdaq GlobeNewswire
AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis

25 авг 2021 11:46:55 Источник Nasdaq GlobeNewswire
AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS

23 авг 2021 12:43:09 Источник Nasdaq GlobeNewswire
AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib

19 авг 2021 10:51:36 Источник Nasdaq GlobeNewswire
AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders

06 авг 2021 12:02:25 Источник Nasdaq GlobeNewswire
AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC

29 июл 2021 11:06:56 Источник Nasdaq GlobeNewswire
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)

22 июл 2021 11:10:35 Источник Nasdaq GlobeNewswire
AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

20 июл 2021 11:08:07 Источник Nasdaq GlobeNewswire
AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo

19 июл 2021 11:12:44 Источник Nasdaq GlobeNewswire
AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France

12 июл 2021 01:00:28 Источник Nasdaq GlobeNewswire
AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib

28 июн 2021 12:59:14 Источник Nasdaq GlobeNewswire
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting

10 июн 2021 11:54:29 Источник Nasdaq GlobeNewswire
AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

08 июн 2021 01:30:40 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on June 3, 2021 following the voluntary hold in the clinical studies of masitinib

02 июн 2021 08:32:44 Источник Nasdaq GlobeNewswire
AB Science announces a voluntary hold in the clinical studies of masitinib worldwide

31 май 2021 23:59:55 Источник Nasdaq GlobeNewswire
AB Science communicates results from Phase 3 study evaluating masitinib in prostate cancer

26 май 2021 12:18:48 Источник Nasdaq GlobeNewswire
AB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate Cancer

21 май 2021 11:01:41 Источник Nasdaq GlobeNewswire
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting

20 май 2021 11:06:59 Источник Nasdaq GlobeNewswire
AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities

30 апр 2021 11:45:24 Источник Nasdaq GlobeNewswire
AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint

29 апр 2021 12:05:11 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
4
5
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.